Does COVID‐19 increase tacrolimus levels in kidney transplant recipients?

Autor:	Bajpai, Divya, Saxena, Nikhil, Gandhi, Chintan, Modi, Tulsi, Bose, Sreyashi, Deb, Satarupa, Rao, Nikhil, Kumar, Kruteesh, Katyal, Abhinav, Patil, Ankita, Thakare, Sayali, Pajai, Atim E., Haridas, Ashwathy, Keskar, Vaibhav S., Jawale, Sunil Y., Sultan, Amar G., Jamale, Tukaram E.
Předmět:	KIDNEY transplantation PATIENTS IMMUNOSUPPRESSION GENETIC polymorphisms TREATMENT effectiveness GENOTYPES COVID-19 pandemic TACROLIMUS TRANSPLANTATION of organs tissues etc. PHARMACODYNAMICS
Zdroj:	Journal of Clinical Pharmacy & Therapeutics; May2022, Vol. 47 Issue 5, p707-708, 2p
Abstrakt:	In the article, the authors present a prospective multicentre study which determined the effect of COVID-19 infection on tacrolimus trough concentrations (C0) in kidney transplant recipients (KTR). Other topics include how supratherapeutic tacrolimus could lead to kidney injury and neurotoxicity, and some other possible adverse effects like diarrhoea and high serum creatinine levels.
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.